[Federal Register Volume 76, Number 58 (Friday, March 25, 2011)]
[Notices]
[Pages 16795-16796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-7068]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0620]


The National Antimicrobial Resistance Monitoring System Strategic 
Plan 2011-2015; Request for Comments; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is extending the 
comment period for the notice that appeared in the Federal Register of 
January 24, 2011 (76 FR 4120). In the notice, FDA requested comments on 
a document for the National Antimicrobial Resistance Monitoring System 
(NARMS) entitled ``NARMS Strategic Plan 2011-2015.'' The Agency is 
taking this action in response to requests for an extension to allow 
interested persons additional time to submit comments. Based on 
requests received, additional information is being placed in the docket 
related to the development of the Strategic Plan. This information can 
also be viewed at the Web sites listed in section III of this document.

DATES: Submit either electronic or written comments by May 24, 2011.

ADDRESSES: Submit electronic comments to http://www.regulations.gov. 
Submit written comments to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Patrick McDermott, Center for 
Veterinary Medicine (HFV-530), Food and Drug Administration, 8401 
Muirkirk Rd., Laurel, MD 20708, 301-210-4213, e-mail: 
[email protected].

[[Page 16796]]


SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of January 24, 2011 (76 FR 4120), FDA 
published a notice with a 60-day comment period to request comments 
from stakeholders on strategies to address a document for the NARMS 
program entitled ``NARMS Strategic Plan 2011-2015.'' The notice 
expressed FDA's interest in receiving comments on the goals and 
objectives in the Strategic Plan and whether the goals and objectives 
meet the recommendations of the subcommittee.
    The Agency has received requests for a 60-day extension of the 
comment period along with request for background material on the 
development of the ``NARMS Strategic Plan 2011-2015.'' The requests 
conveyed concern that the current 60-day comment period does not allow 
respondents sufficient time to address fully the many important issues 
FDA raised in the notice.
    FDA has considered the requests and is extending the comment period 
for the notice for 60 days, until May 24, 2011. The Agency believes 
that a 60-day extension allows adequate time for interested persons to 
submit comments without significantly delaying the Agency's 
consideration of these important issues.

II. Request for Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) either electronic or written comments regarding this 
document. It is only necessary to send one set of comments. It is no 
longer necessary to send two copies of mailed comments. Identify 
comments with the docket number found in brackets in the heading of 
this document. Received comments may be seen in the Division of Dockets 
Management between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

    Persons with access to the Internet may obtain documents at either 
http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/default.htm, http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ucm062630.htm, http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ucm059135.htm, http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b_02_06_NARMS%20Review%20Update.pdf, or http://www.regulations.gov.

    Dated: March 21, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-7068 Filed 3-24-11; 8:45 am]
BILLING CODE 4160-01-P